Skip to main content

ADVERTISEMENT

cemiplimab

Research Reports
12/15/2021
Helmy M Guirgis, MD, PhD
Helmy M Guirgis, MD, PhD, aimed to examine cost of extended immune checkpoint inhibitor use beyond their indications in advanced/metastatic non-small cell lung cancer.
Helmy M Guirgis, MD, PhD, aimed to examine cost of extended immune checkpoint inhibitor use beyond their indications in advanced/metastatic non-small cell lung cancer.
Helmy M Guirgis, MD, PhD, aimed...
12/15/2021
Journal of Clinical Pathways